0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

Combining preventative therapies

Session 4: Difficult to treat patients

Mattias Linde

Professor of neurology​ Norwegian Headache Research Centre​ NTNU, Trondheim​ / Consultant neurologist and ​Chairman RPT Migraine​ Sahlgrenska University Hospital​

Previous

Comorbidities and management

You Might Also Like

Related Embedded Video Item Thumbnail Migraine in elderly
Related Embedded Video Item Thumbnail Epidemiology
Related Embedded Video Item Thumbnail Comorbidities and management
Related Embedded Video Item Thumbnail Rationale for switching of preventative treatments
Related Embedded Video Item Thumbnail Multidisciplinary management

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128